Liraglutide
:Type 2 diabetes
:Filed for registration
Launched in Europe, filed in the US and Japan.
Liraglutide is a once-daily human GLP-1 analogue. The compound is being developed by Novo Nordisk for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high 1,2, and by inhibiting appetite 3.
GLP-1 lowers blood glucose in type 2 diabetes patients with the unique advantage that glucose-lowering ceases when blood glucose gets into the normal range, as both effects on insulin and glucagon release are glucose-dependent 4,5,6,7. Thus, it is possible to treat effectively without simultaneously running a risk of inducing hypoglycaemia. GLP-1 has a positive impact on beta cell function 8,9,10. Also, in contrast to most other antidiabetic treatments, liraglutide also leads to weight loss, an important problem during current treatment of type 2 diabetes 11. Liraglutide also has a beneficial impact on systolic blood pressure, a key cardiovascular risk factor in type 2 diabetes 11,12.
Liraglutide is a derivative of human GLP-1 (97% homology) 13 designed to be protected against DPPIV degradation and elimination by the kidneys resulting in a prolonged half-life 14,15 and thus sustained action of more than 24 hours 16,17. This is primarily due to its binding to serum albumin.
The LEAD® programme (Liraglutide Effect and Action in Diabetes) includes around 4,000 patients with type 2 diabetes whose blood glucose is inadequately controlled. The programme is comprised of five randomised, controlled, double-blind studies conducted in more than 40 countries.
- Company announcements
- Interim financial report for the period 1 January 2009 to 30 September 2009 (29 Oct 2009)
- Update on timeline for formal feedback on liraglutide from the FDA (23 Sep 2009)
- Interim financial report for the period 1 January 2009 to 30 June 2009 (06 Aug 2009)
- Read more company announcements
- Press releases
- New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide (22 Oct 2009)
- New data shows that patients with type 2 diabetes improve their blood sugar control when switched to Victoza® from Byetta® (30 Sep 2009)
- The Lancet publishes direct comparison study between liraglutide and exenatide (09 Jun 2009)
- Read more press releases
- Scientific abstracts
- American Heart Journal (2002)
- American Journal of Hypertension (2008)
- American Journal of Kidney Diseases (2001)
- Read more scientific abstracts
